Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences Inc (NY: RCUS )

14.70 +0.42 (+2.94%)
Official Closing Price Updated: 4:10 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcus Biosciences Inc

< Previous 1 2 3 4 5 Next >
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts
Via Benzinga
Unveiling 5 Analyst Insights On Arcus Biosciences
Via Benzinga
Where Arcus Biosciences Stands With Analysts
Via Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews
Via Benzinga
Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
Via Benzinga
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
Via Benzinga
Navigating 5 Analyst Ratings For Arcus Biosciences
Via Benzinga
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Recap: Arcus Biosciences Q4 Earnings
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Preview: Arcus Biosciences's Earnings
Via Benzinga
Key Takeaways From Arcus Biosciences Analyst Ratings
Via Benzinga
What 9 Analyst Ratings Have To Say About Arcus Biosciences
Via Benzinga
Arcus Biosciences: Q3 Earnings Insights
Via Benzinga
Expert Ratings for Arcus Biosciences
Via Benzinga
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today! 
Via InvestorPlace
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy. 
Via Benzinga
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month... 
Via Benzinga
Where Arcus Biosciences Stands With Analysts
Via Benzinga
5 Analysts Have This to Say About Arcus Biosciences
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.